Join NCF for Caregiver Group. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page MONTHLY Virtual NET Caregiver Support Group Meetings Typically the last Saturday of every month 8:00 - 10:00 AM Pacific 2025 Dates: Jan 18, 2025 Apr 26, 2025 Jul 19, 2025 Oct 18, 2025 Feb 15, 2025 May 31, 2025 Aug 23, 2025 Nov 22, 2025 Mar 22, 2025 Jun 28, 2025 Sep 27, 2025 Dec 20, 2025 We provide a safe space where NET Caregivers can come together virtually for support, connection and community. We encourage you to express your experiences, thoughts and feelings in this safe space. Unlike our weekly networking group, our Caregiver Support Group does not focus on exchanging information on medical resources. Instead, we focus on the unique experiences and concerns of caregivers and provide emotional support to those affected by NET. *OPEN TO NET CAREGIVERS ONLY. The zoom link is provided in the RSVP confirmation and will also be emailed to you prior to the support meeting. Questions? Need technical support? Email events@LACNETS.org . *Limited spots available. REGISTER THANKS TO OUR SUPPORTERS

<< Go back to the Podcast page EPISODE 50 - Spotlight on Pharmacists Download a Transcript of this Episode >>> ABOUT THIS EPISODE What is a pharmacist, and how are they involved in the care of neuroendocrine cancer patients? In this episode, Dr. Amanda Cass, a clinical pharmacist in the Thoracic Oncology Clinic at Vanderbilt Medical Center, explains the unique role pharmacists play—why they’re sometimes called “doctor,” how they support patients starting treatments such as cabozantinib and CAPTEM, and practical tips for staying organized, managing side effects, and navigating medication costs. MEET AMANDA CASS Dr. Cass is a clinical pharmacist in the Thoracic Oncology Clinic at Vanderbilt University Medical Center. She received her Doctorate of Pharmacy from the University of Kentucky College of Pharmacy in 2016 and subsequently completed her Pharmacy Practice Residency at Grady Health System and became a Board Certified Pharmacotherapy Specialist in 2017. In 2018, she completed her Oncology Pharmacy Residency at the University of North Carolina Medical Center. Dr. Cass's previous research interests included opioid use in non-metastatic cancer patients after curative treatment and albumin effects on oxaliplatin related toxicities. Her current areas of interest are molecular mutations and use of targeted therapies in NSCLC, immunotherapy in SCLC, and global oncology care. Dr. Cass is the preceptor for the Outpatient Thoracic Oncology Rotation. TOP TEN QUESTIONS: Getting to Know the Pharmacist 1. What exactly does a pharmacist do, and what training do they go through? 2. Why are pharmacists sometimes called “doctor,” and how is that different from a physician? 3. What role does a pharmacist play on the cancer care team? 4. How are pharmacists involved in caring for neuroendocrine cancer patients, both directly and behind the scenes? How Pharmacists Support Treatment 5. How can a pharmacist help when someone is starting a new treatment for neuroendocrine cancer? Walk us through an example with Cabozantinib: how do you guide patients in understanding it, taking it, and managing side effects? 6. Walk us through another example with CAPTEM (capecitabine and temozolomide): how do you guide patients in understanding it, taking it, and managing side effects? Practical Tips for Patients 7. What are some simple ways to stay organized, like keeping a medication list or symptom journal? 8. What practical tips do you share with patients about tracking and managing side effects at home? Access and Communication 9. Who can patients talk to about medication costs or financial assistance? 10. How does someone find a pharmacist to talk to, and is it important to find one with neuroendocrine cancer experience? RESOURCES EXPLORE Cabometyx Patient Care Kit: www.cabometyx.com/resources Questions to Ask Your Pharmacists Medication reminder apps: Medisafe Dosecast - link for Apple & for iOS EveryDose MedMinder - link for Apple and for iOS Pillo - A.K.A. The Angry Pill Box MyTherapy DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Lu-177 DOTATATE + Sunitinib in PNETs << Back Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors IDENTIFIER ( ClinicalTrials.gov ) : NCT05687123 DRUG/TREATMENT : Lu177 dotatate + sunitinib study PHASE : 1 STATUS : Recruiting SPONSOR : National Cancer Institute (NCI) DESCRIPTION: This phase I trial tests the safety, side effects, and dosimetry of sunitinib malate in combination with lutetium Lu 177 dotatate in treating patients with pancreatic neuroendocrine tumors. Sunitinib malate is in a class of medications called kinase inhibitors and a form of targeted therapy that blocks the action of abnormal proteins called VEGFRs that signal tumor cells to multiply. This helps stop or slow the spread of tumor cells. Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and not harm normal cells. It is also a form of targeted therapy because it works by attaching itself to specific molecules (receptors) on the surface of tumor cells, known as somatostatin receptors, so that radiation can be delivered directly to the tumor cells and kill them. Giving sunitinib malate and lutetium Lu 177 dotatate in combination may be safer and more effective in treating pancreatic neuroendocrine tumors than giving either drug alone. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT : Principal Investigator: Nikolaos Trikalinos,Yale University Cancer Center LAO RELATED RESOURCES Clinical Trials Using Lutetium Lu 177 Dotatate - NCI

<< Go back to the Podcast page EPISODE 47: SPOTLIGHT ON ENDOCRINOLOGY Download a Transcript of this Episode >>> ABOUT THIS EPISODE Every provider on a multidisciplinary neuroendocrine cancer (NET) team brings a distinct and valuable perspective. In this episode, UCLA endocrinologist Dr. Run Yu sheds light on the unique role of the endocrinologist. He explains what endocrinology is, which types of NETs may require an endocrinologist's care, and how endocrine issues intersect with NET management. Dr. Yu also explores the “endocrine” side of neuroendocrine—discussing key concerns related to diabetes, thyroid, parathyroid, and adrenals. MEET DR. RUN YU Run Yu, MD, PhD, received his MD degree from Peking Union Medical College in Beijing and his PhD degree in pharmacology from University of Rochester in New York. Dr. Yu completed an endocrine research fellowship, an internal medicine residency, and a clinical endocrinology fellowship at Cedars-Sinai Medical Center. Dr. Yu’s clinical and research interests include diabetes, thyroid, and endocrine tumors and syndromes. Dr. Yu enjoys describing novel clinical findings in endocrinology. TOP TEN QUESTIONS: What is an endocrinologist? What training is involved? Since there is “endocrine” in neuroendocrine, would NET patients need to see an endocrinologist? When should one see an endocrinologist? What is your role with your medical team? How is an endocrinologist different from a medical oncologist? If someone with neuroendocrine cancer needs to see an endocrinologist, does that person need to specialize in neuroendocrine cancer? 3. If someone sees both an endocrinologist and a medical oncologist, what do you do and what does the medical oncologist do? How are treatment decisions made or coordinated? (Who is the “quarterback?”) 4. Who orders the somatostatin injections? Are they done through the oncologist or endocrinologist? What if I need something else to control my neuroendocrine cancer symptoms? 5. What are hormonal issues? How do I know if my neuroendocrine tumor produces hormones? 6. What hormone tests do you check? 7. What tumor markers do you check? How do you interpret them? 8. When might endocrine issues arise with neuroendocrine cancer? Thyroid Parathyroid Adrenal 9. How do hyperglycemia and diabetes issues relate to neuroendocrine cancer? What is hyperglycemia, pre-diabetes and diabetes? Is diabetes inevitable with NET? Is diabetes inevitable with somatostatin analogue therapy? Does metformin potentially slow down NET tumor growth? What monitoring do you recommend? 10. When does one encounter hypoglycemia with neuroendocrine cancer? What is insulinoma? What is the treatment? BONUS: What is on the horizon for neuroendocrine cancer that you’re most optimistic about? RESOURCES https://www.youtube.com/watch?v=IfP_0DGwml0 "The Endocrine in Neuroendocrine" • Run Yu, MD, Endocrinologist, UCLA • 2024 NET Cancer Day Symposium https://www.youtube.com/watch?v=2hUoow6TiZI "Q&A with Experts" • Andrew Hendifar, MD, Run Yu, MD, & Jaydira Del Rivero, MD • 2024 NET Cancer Day DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 42: NEUROENDOCRINE CANCER STRAIGHT TALK Download a Transcript of this Episode >>> ABOUT THIS EPISODE In this special episode, medical oncologist and NET expert, Dr. Diane Reidy-Lagunes engages in an open and honest discussion on sensitive topics including sexual health, family planning and end-of-life discussions. She also answers common questions regarding cannabis use with cancer as well as the relationship between sugar and cancer. Dr. Reidy shares information and insights from her decades of experience as well as from the award-winning “Cancer Straight Talk” podcast from Memorial Sloan Kettering Cancer Center (MSKCC) she created and hosted, and she relates these topics to NET patients and their loved ones. MEET DR. DIANE REIDY-LAGUNES Dr. Diane Reidy-Lagunes will join the Department of Medicine (DOM) as chief of the Division of Medical Oncology, effective April 1, 2025. In addition to her role with DOM, Dr. Reidy-Lagunes will also hold an appointment as Associate Vice President for Oncology Services for Duke University Health System. Dr. Reidy-Lagunes comes to Duke from Memorial Sloan Kettering Cancer Center (MSKCC), where she served as the vice chair of Medicine focused on coordination of care in MSKCC Regional Care Network. Her previous roles included president of MSKCC’s Medical Staff, associate deputy physician-in-chief for clinical operations in the Regional Care Network, physician liaison for the Patient and Family Advisory Council on Quality, clinical director for the GI oncology service, and co-director of the Medical Oncology/Hematology Fellowship Program in the Department of Medicine. During the COVID-19 crisis in New York City, she served as chief of clinical care as part of the Hospital Incident Command System at MSKCC. Additionally, she is the creator and host of an award-winning monthly podcast called "Cancer Straight Talk" from MSKCC which connects patients to cancer experts with the goal of having evidenced-based conversations on a variety of topics in cancer care. As a researcher, Dr. Reidy-Lagunes focuses on developing methods to integrate molecular-based therapies into the treatment of neuroendocrine and adrenal tumors. She is a member of the National Cancer Institute Task Force on Neuroendocrine Tumors and the National Cancer Care Network Guidelines, and she is a former board member of the North American Neuroendocrine Tumor Society. She has received numerous awards and honors, including the Paul Sherlock Resident Housestaff Teaching Award and recognition as one of Castle Connolly's Top Doctors. TOP TEN QUESTIONS: What is cancer? Is NET cancer? Should I follow a certain diet? Does sugar feed cancer? Can I exercise if I have metastatic neuroendocrine cancer? What does having neuroendocrine cancer mean for my romantic life? How does it affect dating? What does having neuroendocrine cancer mean for my sexual health? What does having neuroendocrine cancer mean for fertility and family planning? Can I have children? How do I talk to my kids about cancer? How will I know when it’s time for end-of-life discussions? Should I consider cannabis? What advice do you have about improving communication with my doctor? RESOURCES LISTEN MSK’s Cancer Straight Talk Podcast Series with Dr. Diane Reidy Episodes mentioned in this podcast: Episode 2 - Understanding the Basics of the “C-word”: What is Cancer with Dr. Matthew Matasar Episode 6 - Sugar and Cancer: Friend or Foe with Dr. Santosha Vardhana Episode 5 -Making Every Step Count: The Role of Exercise and Cancer Episode 34 - How Exercise Can Help Treat and Prevent Cancer with Dr. Lee Jones Episode 35 - Dating After a Cancer Diagnosis Episode 20 - A Man’s Guide to Sex and Cancer Episode 59 - Preserving Fertility During Cancer Treatment: Options, Costs and Success Rates Episode 56 - How to Talk to Children About Cancer Episode 23 - What’s the Hash on the Little Green Plan (Cannabis) and Cancer? MSK’s Death over Dinner The LACNETS Podcast Episode 37: Supportive Oncology for Neuroendocrine Cancer WATCH https://www.youtube.com/watch?v=ef4GurXr0C8 https://www.youtube.com/watch?v=FiYogD5g_9A DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas << Back Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas IDENTIFIER ( ClinicalTrials.gov ) : NCT06041516 DRUG/TREATMENT : ADCT-701 is given through a tube attached to a needle inserted into a vein in the arm. PHASE : First-in-Human Phase I Trial STATUS : Recruiting SPONSOR : National Cancer Institute (NCI) https://www.youtube.com/watch?v=ZmffIH9J3v8 DESCRIPTION: This is a first in human phase 1 study to test a new drug, ADCT-701, in people with Neuroendocrine neoplasms (NENs). ADCT-701 is an antibody drug conjugate (or ADC) that specifically targets "Delta Like Non-Canonical Notch Ligand 1" or DLK1, an antigen which has recently been found to be expressed on neuroendocrine cancers. The hope is this drug will suppress tumor growth, shrink tumors after tumor growth, and improve survival. *Note: This study includes all neuroendocrine neoplasms including neuroendocrine tumors, neuroendocrine carcinomas (i.e. "high grade neuroendocrine cancers"), pheochromocytoma, paraganglioma and adrenocortical carcinoma (ACC). For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT : National Cancer Institute Medical Oncology Kimberley J Cooper EMAIL: kimberley.cooper@nih.gov PHONE: 240-858-5798 Principal investigator: Jaydira Del Rivero, M.D.,National Cancer Institute (NCI) LOCATIONS : National Instititues of Health Clinical Center: Bethesda, Maryland, United States 20892

<< Go back to the Podcast page EPISODE 19 - BEYOND THE BASICS: THE PATHOLOGY OF NET Download a Transcript of this Episode >> ABOUT THIS EPISODE Take a glimpse through the microscope and learn how pathology determines your NET diagnosis and guides treatment. How does one interpret differing Ki-67 results from the same specimen? Why might a patient have two different Ki-67 results from different specimens? How does pathology distinguish G3 well-differentiated NET from NEC? How does pathology help with NET tumors of unknown origin? NET pathologist Dr. Andrew M. Bellizzi from the University of Iowa sheds light on just how much information a tiny tissue sample may contain. MEET DR. ANDREW M. BELLIZZI Andrew M. Bellizzi, M.D. is a Clinical Professor in the Department of Pathology at the University of Iowa. Dr. Bellizzi completed undergraduate work in Anthropology and Science Preprofessional Studies at the University of Notre Dame (‘00) and received his medical degree from Northwestern University (‘04). Following combined training in Anatomic and Clinical Pathology at the University of Virginia (‘08), he completed a fellowship in Gastrointestinal and Liver Pathology at The Ohio State University (‘09). After two years as a junior faculty at Brigham and Women’s Hospital, he moved to Iowa in the Fall of 2011. Dr. Bellizzi is the Director of Immunohistochemistry, GI Pathology, and the GI Pathology Fellowship at the University of Iowa. He is an active member of the United States and Canadian Academy of Pathology, the American Society of Clinical Pathology, and the College of American Pathologists, including servingas the immediate past Chair of the USCAP Stowell-Orbison Award and the CAP Immunohistochemistry Committees. He is the Secretary-Treasurer of the International Society for Immunohistochemistry and Molecular Morphology and is an Associate (Reviews), Section (Immunohistochemistry), and Assistant Editor(GI pathology) of Applied Immunohistochemistry and Molecular Morphology, Archives of Pathology and Laboratory Medicine, and the American Journal of Clinical Pathology, respectively. Dr. Bellizzi’s research interests include the diagnosis, classification, and etiopathogenesis of human disease, with an emphasis on gastrointestinal, pancreatic, neuroendocrine, and hereditary tumors. His research program focuses on applications of diagnostic immunohistochemistry. Outside of the office, Andrew enjoys “getting into trouble” with his 14 and 16- year-old boys, Aidan and Darby. In addition to “very special stains,” he also loves hiking, cooking, craft beer, Notre Dame football, the Boston Red Sox, and the Oxford comma. TOP 10 QUESTIONS 1. What is Oncopathology? 2. What is immunohistochemistry, and what do patients need to know about it? 3. What is your opinion when you see that there are differing Ki-67 of the same tumor specimen? For example, one institution reports a Ki-67 of 3 and another one reports a Ki-67 of 10? 4. What would you say if you see that an individual has 2 to 3 biopsies with differing Ki-67? For example, a Ki-67 of 3, 5, and 8? Is there a problem with standardization? 5. When would you re-biopsy? Would we re-biopsy because of this? 6. Discuss G3 tumors. How are well-differentiated vs. poorly differentiated G3 tumors different, and how do you figure this out? 7. Discuss metastatic tumors of unknown origin. How can a pathologist help with tumors of unknown origin, particularly in NEC? 8. Should I get a second opinion on my pathology? If so, how is that done? 9. How long are pathology specimens typically stored? (What should I do if I get a phone call that now that it’s been over 10 years, the hospital will no longer store my specimen?) 10. What future advances do you look forward to that might bring hope to the NET Community? RESOURCES READ How to Read Your Pathology Report WATCH https://www.youtube.com/watch?v=VkgoByozjX0 "Your Pathology & Your Pathology Report" with Dr. Sue Chang, City of Hope Recorded March 2020 LISTEN DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Join NCF for SNMMI. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page REGISTER https://www.youtube.com/watch?v=IyNx3LQU-Ys Dr. Eric Liu and Dr. Erik Mittra discuss the upcoming Neuroendocrine Cancer Patient Education Day at the 2026 SNMMI, highlighting what attendees will learn about neuroendocrine cancer. Have questions about your scans, treatments, or what comes next? Wondering about DOTATATE scans, PRRT, or radiation safety? Curious about clinical trials, what options are available now, and what is on the horizon? Not sure what comes after PRRT, or what treatments may be considered if your tumor does not express somatostatin receptors? We will answer practical questions that matter in your day-to-day life. Join us in Los Angeles on Sunday, May 31, for a dynamic patient education event, a collaboration between NorCal Carcinet and the Neuroendocrine Cancer Foundation, and in partnership with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), a leading medical and scientific organization dedicated to advancing nuclear medicine and molecular imaging. Each year, Josh Mailman, President of NorCal CarciNET, organizes this event alongside the SNMMI Annual Conference. With this year’s conference taking place at the Los Angeles Convention Center, we are honored to collaborate on this meaningful program. The event will be hybrid and completely free, with options to attend in person or via livestream. For those attending in person, parking, lunch, and a networking reception are all provided at no cost. Location: Los Angeles Convention Center 1201 S. Figueroa St. Los Angeles, CA 90015 Parking will be validated only to those who register for the event in advance. Speakers Richard Baum, MD, Curanosticum Wiesbaden, Germany Lisa Bodei, MD, PhD, Memorial Sloan Kettering Cancer Center, NY Gabriel Fine, MD, City of Hope Cancer Center, Duarte, CA George Fisher, MD, PhD, Stanford Cancer Center, Palo Alto, CA Eric Liu, MD, Healing NET Foundation, Denver, CO Erik Mittra, MD, PhD, Oregon Health & Science University, Portland, OR Why attend in person? Get your questions answered by leading neuroendocrine cancer experts Learn about the latest advances in imaging, treatment, and clinical trials Connect with other patients, caregivers, and professionals who understand the journey Explore the exhibit hall and hear directly from scientists as they break down their research in a patient-friendly way This is more than just an educational event. It is an opportunity to feel more informed, more confident, and more empowered to actively engage in your care. Agenda 9:30 - 9:50 am Guided Exhibit Hall Tour (in person only) - South Exhibit Hall Pick up badges at the SNMMI Hub, located at the front of the South Exhibit Hall at 9:15 a.m. 10:00 - 11:45 am General Session - Room 152 10:00 - 10:10 am - Welcome and Announcements 10:10-11:00 am - What is Nuclear Medicine and Molecular Imaging? / Radiation Safety Martin Tornai, PhD, National Institute of Biomedical Imaging and Bioengineering National Institutes of Health 11:00 - 11:45 am - How to Understand and Evaluate Clinical Trials George Fisher, MD, PhD, Stanford Cancer Center, Palo Alto, CA 11:45 am - 1:00 pm Lunch - Complimentary Buffet (in person only) - Room 152 12:15 - 12:45 pm - Seeing is Believing: Innovations in Imaging to Improve Patient Care (in person only) Simon Cherry, PhD, The Cherry Laboratory, University of California Davis 1:00 - 4:30 pm NETS - Exploring the Latest Innovations in Diagnosis and Treatment - Room 152 1:15 - 1:20 pm - Patient Story 1:20 - 1:40 pm - Neuroendocrine Tumor Overview George Fisher, MD, PhD, Stanford University 1:40 - 2:00 pm- "Meet the Author" Poster Presentations Lisa Bodei, MD, PhD, Sloan Kettering Cancer Center, New York, NY Frank Lin, MD, National Institute of Cancer 2:00 - 2:20 pm - Optimizing Your Health for your NET Journey Eric Liu, MD, Healing NET Foundation 2:20 - 2:40 pm - Break 2:40 - 3:00 pm- The Role of Interventional Radiology Gabriel Fine, MD, City of Hope Cancer Center, Duarte, CA 3:00 - 3:10 pm - Overview of Theranostics in the USA and Europe Lisa Bodei, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY 3:10 - 3:30 pm - Theranostics and Clinical Trials: Where We are Now in the USA Erik Mittra, MD, PhD, Oregon Health & Science University 3:30 - 3:50 pm - The Expanding Role of Theranostics in G3 NET and Beyond Richard Baum, MD, PhD, Curanosticum Wiesbaden, Germany 3:50 - 4:30 pm - Q&A 4:30 - 5:30 pm - Reception (in person only) - Room 153-C Enjoy complimentary hors d'oeuvres and drinks REGISTER

Join NCF for May2024. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=oSqUgq6QdnM Learn about the latest in high grade neuroendocrine neoplasms and small cell lung cancer with medical oncologist Dr. Aman Chauhan, Leader of the Neuroendocrine Tumor Program and Co-Director of the Theragnostic Program at the Sylvester Comprehensive Cancer Center, University of Miami. ABOUT DR. AMAN CHAUHAN Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. SPONSORS The information provided is for educational purposes only and does not substitute for medical advice. Talk to your medical team if you have any questions or concerns about your individual care and treatment. The opinions expressed in this program are those of the speakers and do not represent the opinion of LACNETS.

<< Go back to the Podcast page EPISODE 54 - Focus on Cabozantinib Download a Transcript of this Episode >>> ABOUT THIS EPISODE Since its FDA approval on March 26, 2025, cabozantinib has emerged as the newest treatment option for neuroendocrine tumor (NET) patients—adding another valuable tool to the treatment toolbox. It’s become a hot topic in support groups and forums, with many patients wondering what to expect. In this episode, Fox Chase Cancer Center medical oncologist Dr. Namrata (“Neena”) Vijayvergia answers the most frequently asked questions about cabozantinib. She explains how it works, how it differs from other therapies, what patients should know about dosing and side effects, and shares insights on a new clinical trial exploring the next generation of cabozantinib, z anzalintinib or "zanza ." TOP TEN QUESTIONS What is cabozantinib? Is it considered chemotherapy? How does cabozantinib work? What do we mean by “targeted therapies”? Who is cabozantinib typically recommended for? When in someone’s NET journey do you consider starting it? Why might a patient take cabozantinib instead of other treatment options? Is this a “last resort” treatment option? Does it limit future choices or “burn any bridges”? What are the most common side effects? Will I look like a cancer patient? Will my hair fall out? How might I feel while taking it—can most people keep working and doing their usual activities? Do common side effects tend to develop or get worse over time, or pretty much stay the same? What should patients watch out for or monitor while taking this medication? What should patients know about dosing? Is there a preferred starting dose or an “optimal” dose? If I tolerate a lower dose, should I go to a higher dose? What happens if cabozantinib doesn’t work for me? What other treatments might be available? I’ve heard about a drug called “Zanza,” the STELLAR-311 trial. What is it, and how does it fit into the current treatment landscape? What practical tips or “tricks of the trade” do you share with patients who may start this medication? Bonus: What’s on the horizon in NET research or treatment that you’re most excited about? MEET DR. NAMRATA (NEENA) VIJAYVERGIA Namrata (Neena) Vijayvergia, MD, FACP Gastrointestinal Medical Oncologist Fox Chase Cancer Center Philadelphia, PA Namrata (Neena) Vijayvergia, MD, FACP, is a GI medical oncologist, clinical trialist, and physician leader known for bringing science, collaboration, and heart to the care of patients with gastrointestinal and neuroendocrine cancers. She is Section Chief of Gastrointestinal Oncology at Fox Chase Cancer Center and an Associate Professor, where she leads a broad research program—from early-phase therapeutics to biomarker-driven strategies and patient-centered outcomes—supported by NIH, NCCN, industry partners, and foundations. Neena is a frequent speaker at national and international meetings, including ASCO, NANETS, ESMO, and SNMMI, and was recently honored with the 2025 Distinguished Clinical Award from NANETS. She helps set national standards through service on ASCO, NCCN, ENETS, NCI, and NANETS committees and guideline panels, chairs the NANETS Scientific Review Committee, and leads cooperative group efforts within ECOG-ACRIN. A dedicated mentor and advocate, she supports trainees and junior faculty through formal mentoring programs, advises patient advocacy organizations, and engages in community-focused efforts to make cancer care more inclusive and equitable. Recognized in the ASCO Leadership Development Program and as a “40 Under 40 in Cancer,” she brings a strategic yet people-first approach to clinical trial development—always driven by the belief that teamwork, curiosity, and compassion can move the field forward for patients and the teams who care for them. RESOURCES Learn More About Cabozantinib and The Cabinet Trial EXPLORE CABOMETYX.com provides patient-friendly information about CABOMETYX® (cabozantinib), an FDA-approved prescription treatment for certain previously treated pancreatic and extra-pancreatic neuroendocrine tumors that cannot be treated by surgery and have spread. The site includes information on how CABOMETYX may help, possible side effects, treatment support, financial assistance resources, patient videos, and a doctor discussion guide. Patients should review this information with their healthcare team to determine whether CABOMETYX may be appropriate for their individual situation. Visit https://www.cabometyx.com/neuroendocrine-tumors >>> WATCH https://www.youtube.com/watch?v=balUaCFLceI Dr. Aman Chauhan Provides an Update on Cabozantinib https://www.youtube.com/watch?v=EK0wHgui9d4 Lisa Yen Provides Practical Tips for Cabozantinib LISTEN Episode 50: Spotlight on Pharmacists READ Read March 26, 2025 blogpost: Positive Results of the CABINET Trial Show Cabozantinib as a New, Effective Treatment in Advanced Neuroendocrine Tumors "Gastroenteropancreatic Neuroendocrine Tumors" Review article by Vijayvergia et al CLINICAL TRIAL STELLAR-311: Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Cancers DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

< Back to the supporters page ABOUT CURIUM "At Curium, we have a singular focus – to develop, manufacture and supply world-class radiopharmaceutical products around the globe. We strive to innovate further in nuclear diagnostics and therapies so we can enhance the lives of people with cancer." https://www.youtube.com/watch?v=nZrQMemmPBw Download the Detectnet™ Brochure >>> Download the Oncology Patient Education Brochure >>> Download the Nuclear Medicine Patient Education Brochure >>> CONTACT Jenny Yessaian RN, MBA Sr Director of Marketing C: +1.626.696.0535 111 Westport Plaza, Suite 800 St. Louis, MO 63146 This information is for educational purposes only and does not substitute for medical advice or constitute an endorsement by the Neuroendocrine Cancer Foundation. Talk to your medical team about your individual care and treatment. Confirm Your Visit to the Novartis Virtual Booth! First name Last name Email Submit << Previous Next >>

Join NCF for July2025. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page ABOUT Patients share their experiences on topics, including decision-making, coping strategies, lessons learned, challenges, and navigating relationships while living with neuroendocrine cancer. Hear about their personal journeys—filled with resilience, realities, and hope, that offer powerful insight into what it's like living with neuroendocrine cancer. SPEAKERS DAVID David was born and raised in California, spending most of his life in San Diego where he and his wife raised two beautiful daughters. Most recently, the family has welcomed a new grandson who has provided much joy to an already happy family. In addition, a new puppy has successfully turned life upside down with his unbridled enthusiasm for simply being a “part of the pack.” Professionally, David worked at the University of California for many years, practicing and teaching medicine until the time of his diagnosis with neuroendocrine cancer. Opening a new chapter in life, David now spends much of his time as a patient advocate, continuing to seek avenues to educate patients with the same diagnosis. In addition, he now serves on several task force committees, including the National Cancer Institute at the National Institutes of Health, serving to help provide the patient voice to proposed studies designed to advance our knowledge and treatment options for patients with NET’s. In his free time, David is an avid photographer, taking pictures since his first camera purchase at the age of 8. Currently, his passion is in the growing area of astrophotography, travelling to some of the darkest skies in the world in search of the light from our universe, trying to capture and record its beauty. DUSTY Dusty Hurley is wife to a charming Irishman; mom to two loving, fun, and bright elementary-aged daughters; and the favorite human of two fluffy, playful dogs. Her professional background includes ministry, nonprofit and government leadership, and grant writing. She enjoys spending time with friends and family…bonus points if it can be around a campfire or traveling to somewhere new. Diagnosed with a pancreatic neuroendocrine tumor (pNET) in 2022, Dusty brings faith, optimism, and determination to her roles as both patient and advocate. She’s passionate about helping others navigate NET with clarity, courage, and hope. JUD After a year of worsening carcinoid syndrome symptoms and diagnostic dead ends, Jud was diagnosed with Stage IV, Grade 3 Small Bowel NET (with metastasis to his mesentery and liver) in the fall of 2022. Almost immediately, Jud decided to enroll in the NETTER-2 clinical trial of Lu-177 Dotatate as a first line NET treatment. Following radioligand therapy and resection / ablation procedures, Jud is reveling in his current lack of tumors and being able to channel his "cancer world" energy into patient education and advocacy efforts. Jud lives with his family in Saint Paul, Minnesota and his day job is as a public finance advisory to cities and counties. He enjoys reading, indoor rowing, and walking his golden retriever around the neighborhood. KIMBERLY Kimberly was born and raised on Oahu, Hawaii. She and her husband, Blake, live with their 3 sons in Mesa, Arizona. Kimberly finds joy in helping and mentoring others, showcased through her 20+ years as an educator and in her current role as a consultant for Banner Health. After her diagnosis with metastatic pNETs in 2020, she has found great purpose in encouraging others to “live well” with NETs through faith, gratitude, peace, and a positive perspective. When she’s not working, doing laundry, or food prepping, you can find her at the gym, quilting, or running around a pickleball court! T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS